Wall Street is in a market manipulation business rather than in investment. Their "perception" that in "a long run" MRK will be a number two player in HCV has no substance.
GILD shows that the HCV market is very sizable with ABBV/Enta getting a good portion of it in the next 12 months. The only issue is whether ABBV will fight Gild or just "share" the market.
Market Data 
Markets 
AI
